PropertyValue
?:abstract
  • Pulmonary thromboembolism is a common complication of many conditions and diseases, and a common cause of death If the lower respiratory tract is affected during the COVID-19 pandemic, patients are diagnosed with pulmonary thromboembolism, the mechanisms of which are not fully disclosed Prescribing anticoagulant therapy reduces the risk of death in venous thromboembolism due to various factors The results of clinical trials proved the effectiveness and safety of the use of new oral anticoagulants as first-line drugs Rivaroxaban is one of the most studied drugs, the pharmacokinetic properties and predictable effects of which justify its use in different clinical conditions © 2020, Professionalnye Izdaniya All rights reserved
is ?:annotates of
?:creator
?:journal
  • Kardiologija_v_Belarusi
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Pulmonary thromboembolism and covid-19: Place for anticoagulant therapy
?:type
?:who_covidence_id
  • #832286
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/hcqzkid0>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/hcqzkid0>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all